JP2023507569A5 - - Google Patents
Info
- Publication number
- JP2023507569A5 JP2023507569A5 JP2022537497A JP2022537497A JP2023507569A5 JP 2023507569 A5 JP2023507569 A5 JP 2023507569A5 JP 2022537497 A JP2022537497 A JP 2022537497A JP 2022537497 A JP2022537497 A JP 2022537497A JP 2023507569 A5 JP2023507569 A5 JP 2023507569A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- composition according
- alkyl
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025075567A JP2025107315A (ja) | 2019-12-19 | 2025-04-30 | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950886P | 2019-12-19 | 2019-12-19 | |
| US62/950,886 | 2019-12-19 | ||
| PCT/US2020/066182 WO2021127543A1 (en) | 2019-12-19 | 2020-12-18 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025075567A Division JP2025107315A (ja) | 2019-12-19 | 2025-04-30 | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023507569A JP2023507569A (ja) | 2023-02-24 |
| JP2023507569A5 true JP2023507569A5 (https=) | 2023-12-21 |
| JP7737721B2 JP7737721B2 (ja) | 2025-09-11 |
Family
ID=76478828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537497A Active JP7737721B2 (ja) | 2019-12-19 | 2020-12-18 | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 |
| JP2025075567A Pending JP2025107315A (ja) | 2019-12-19 | 2025-04-30 | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025075567A Pending JP2025107315A (ja) | 2019-12-19 | 2025-04-30 | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230098667A1 (https=) |
| EP (1) | EP4077333A4 (https=) |
| JP (2) | JP7737721B2 (https=) |
| CN (1) | CN115175911A (https=) |
| AU (1) | AU2020405233A1 (https=) |
| IL (1) | IL294031A (https=) |
| MX (1) | MX2022007725A (https=) |
| WO (1) | WO2021127543A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2020234880A1 (en) * | 2019-05-23 | 2020-11-26 | Life Guard Electrooptic Ltd. | System and a method for surveilling swimmers |
| US20260033761A1 (en) | 2022-07-29 | 2026-02-05 | Hoffmann-La Roche Inc. | Characterisation of neurological dysfunction |
| CN120584115A (zh) * | 2022-08-19 | 2025-09-02 | 艾吉因生物股份有限公司 | 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ760341A (en) * | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| MX392119B (es) * | 2015-06-19 | 2025-03-11 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN112601749B (zh) * | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 |
| CN116075302A (zh) * | 2020-07-10 | 2023-05-05 | 艾吉因生物股份有限公司 | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 |
| WO2022011314A1 (en) * | 2020-07-10 | 2022-01-13 | Agenebio, Inc. | POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT |
-
2020
- 2020-12-18 JP JP2022537497A patent/JP7737721B2/ja active Active
- 2020-12-18 AU AU2020405233A patent/AU2020405233A1/en active Pending
- 2020-12-18 EP EP20904223.3A patent/EP4077333A4/en active Pending
- 2020-12-18 CN CN202080096714.0A patent/CN115175911A/zh active Pending
- 2020-12-18 US US17/786,175 patent/US20230098667A1/en active Pending
- 2020-12-18 IL IL294031A patent/IL294031A/en unknown
- 2020-12-18 MX MX2022007725A patent/MX2022007725A/es unknown
- 2020-12-18 WO PCT/US2020/066182 patent/WO2021127543A1/en not_active Ceased
-
2025
- 2025-04-30 JP JP2025075567A patent/JP2025107315A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507569A5 (https=) | ||
| US20250340558A1 (en) | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof | |
| JP2021528427A5 (https=) | ||
| JP3397320B2 (ja) | 縮合イミダゾリウム誘導体 | |
| AU2015335783B2 (en) | Tricyclic atropisomer compounds | |
| JP2017500334A5 (https=) | ||
| WO2000075113A1 (en) | Novel heterocyclic carboxamide derivatives | |
| JP2016128414A (ja) | ピリミジン誘導体の製造プロセス | |
| CN116194459A (zh) | 抗血小板药物和其用途 | |
| JP2018521034A5 (https=) | ||
| JP5124471B2 (ja) | 置換二環式ピリミドン誘導体 | |
| JP2013542267A5 (https=) | ||
| WO2023061406A1 (zh) | 含三并环结构的parp抑制剂、及其制备方法和医药用途 | |
| WO2021231726A1 (en) | Enpp1 modulators and uses thereof | |
| JP2022505257A5 (https=) | ||
| JP2023509944A5 (https=) | ||
| MX2025006404A (es) | Compuestos de pirrolil-sulfonamida fusionados | |
| JP2022510587A5 (https=) | ||
| JP2023534189A5 (https=) | ||
| CN114805352A (zh) | 作为pi3k/mtor抑制剂的吡咯并吡啶取代的稠合喹啉化合物 | |
| JP2016539994A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| JP2022515549A (ja) | パントテンアミドアナログ | |
| JP2026501678A (ja) | インテグラーゼ阻害剤及びその使用 | |
| JP2001512491A (ja) | １−（イソキノリン−１−イル）−４−（１−フェニメチル）ピペラジン；ドーパミン受容体サブタイプ特異的リガンド | |
| WO2010102513A1 (zh) | 高哌嗪乙酰肼类衍生物及其制备方法和用途 |